JP2017530142A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530142A5
JP2017530142A5 JP2017517228A JP2017517228A JP2017530142A5 JP 2017530142 A5 JP2017530142 A5 JP 2017530142A5 JP 2017517228 A JP2017517228 A JP 2017517228A JP 2017517228 A JP2017517228 A JP 2017517228A JP 2017530142 A5 JP2017530142 A5 JP 2017530142A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
quizartinib
administered
volasertib
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017517228A
Other languages
English (en)
Japanese (ja)
Other versions
JP6708634B2 (ja
JP2017530142A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/072386 external-priority patent/WO2016050749A1/en
Publication of JP2017530142A publication Critical patent/JP2017530142A/ja
Publication of JP2017530142A5 publication Critical patent/JP2017530142A5/ja
Application granted granted Critical
Publication of JP6708634B2 publication Critical patent/JP6708634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017517228A 2014-10-01 2015-09-29 急性骨髄性白血病及び骨髄異形成症候群の併用療法iii Active JP6708634B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14187331.5 2014-10-01
EP14187331 2014-10-01
PCT/EP2015/072386 WO2016050749A1 (en) 2014-10-01 2015-09-29 Combination treatment of acute myeloid leukemia and myelodysplastic syndrome iii

Publications (3)

Publication Number Publication Date
JP2017530142A JP2017530142A (ja) 2017-10-12
JP2017530142A5 true JP2017530142A5 (enExample) 2018-11-08
JP6708634B2 JP6708634B2 (ja) 2020-06-10

Family

ID=51730328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017517228A Active JP6708634B2 (ja) 2014-10-01 2015-09-29 急性骨髄性白血病及び骨髄異形成症候群の併用療法iii

Country Status (4)

Country Link
US (1) US9867831B2 (enExample)
EP (1) EP3200879B1 (enExample)
JP (1) JP6708634B2 (enExample)
WO (1) WO2016050749A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
WO2017214433A1 (en) * 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8303657A (nl) 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
JPH0276860A (ja) 1987-10-05 1990-03-16 Toyo Jozo Co Ltd 6−置換アルコキシ−2−オキソ−1,2−ジヒドロキノキサリン誘導体
EP0347146B1 (en) 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
FR2645152B1 (fr) 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
US5043270A (en) 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
CA2029651C (en) 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (enExample) 1992-09-26 1996-04-21 Hoechst Ag
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9418499D0 (en) 1994-09-14 1994-11-02 Ciba Geigy Ag Process for producing n-methylated organic pigments
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
CZ289721B6 (cs) 1995-05-19 2002-03-13 Syngenta Participations Ag Způsob katalytické hydrogenace aromatických nitrosloučenin
US5698556A (en) 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
HU226167B1 (hu) 1996-09-23 2008-05-28 Lilly Co Eli Olanzapin-dihidrát D, elõállítása és az azt tartalmazó gyógyszerkészítmények
OA11591A (en) 1998-08-11 2004-07-30 Pfizer Prod Inc Substituted 1,8-naphthyridin-4(H)-ones as phosphodiesterase 4 inhibitors.
EA005287B1 (ru) 1999-09-15 2004-12-30 Уорнер-Ламберт Компани Птеридиноны в качестве ингибиторов киназ
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
YU66502A (sh) 2000-03-06 2005-09-19 Warner-Lambert Company 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
DE10018783A1 (de) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de) 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US6960589B2 (en) 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1427730B1 (de) 2001-09-04 2006-07-12 Boehringer Ingelheim Pharma GmbH & Co.KG Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DK1908463T3 (da) 2001-12-14 2011-11-28 Merck Serono Sa Fremgangsmåder til at inducere ægløsning ved anvendelse af en ikke polypeptid-CAMP-niveaumodulator
EP1501794A1 (de) 2002-05-03 2005-02-02 Schering Aktiengesellschaft Thiazolidinone und ihre verwendung als polo like kinase inhibitoren
FR2843114B1 (fr) 2002-08-01 2004-09-10 Poudres & Explosifs Ste Nale Procede de monomethylation d'heterocycles azotes
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
MXPA05002887A (es) 2002-09-16 2005-05-27 Glaxo Group Ltd Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa.
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
UA80743C2 (en) 2003-02-26 2007-10-25 Boehringer Ingelheim Pharma Dihydropteridinones, method for the production and use thereof in the form of drugs
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
PL1605971T3 (pl) 2003-03-26 2010-10-29 Wyeth Llc Kompozycja immunogenna i sposoby
EP1617820B1 (en) 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
WO2005067935A1 (de) 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004002557A1 (de) 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
JP2008510771A (ja) 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
JP2009503014A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療におけるジヒドロプテリジノン
US20070117776A1 (en) 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
SI1948180T1 (sl) 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2007102767A1 (en) 2006-03-07 2007-09-13 Astrazeneca Ab Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
JP4642085B2 (ja) 2008-01-17 2011-03-02 日本下水道事業団 予測健全度を利用した施設管理および更新計画システム
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
ES2624622T3 (es) 2008-12-30 2017-07-17 Rigel Pharmaceuticals, Inc. Inhibidores de pirimidindiamina cinasa
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
US8431595B2 (en) 2009-08-20 2013-04-30 The University Of Tennessee Research Foundation Furanopyridine cannabinoid compounds and related methods of use
US20130012465A1 (en) 2009-12-07 2013-01-10 Boehringer Ingelheim International Gmbh Bibw 2992 for use in the treatment of triple negative breast cancer
US20120329803A1 (en) 2010-02-17 2012-12-27 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
MY181439A (en) * 2011-02-28 2020-12-22 Sunshine Lake Pharma Co Ltd Substituted quinoline compounds and methods of use
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib

Similar Documents

Publication Publication Date Title
JP2012193216A5 (enExample)
JP2015038135A5 (enExample)
JP2015187157A5 (enExample)
JP2015523407A5 (enExample)
JP2006504795A5 (enExample)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2013231087A5 (enExample)
JP2014526503A5 (enExample)
JP2016147915A5 (enExample)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2013516493A5 (enExample)
JP2017512194A5 (enExample)
JP2018521007A5 (enExample)
JP2018138596A5 (enExample)
JP2016515550A5 (enExample)
JP2016505050A5 (enExample)
JP2018039810A5 (enExample)
RU2019101226A (ru) Ингибиторы wnt для применения при лечении фиброза
JP2014520874A5 (enExample)
JP2019507786A5 (enExample)
JP2015512948A5 (enExample)
JP2019529569A5 (enExample)
JP2017530142A5 (enExample)
JP2014503589A5 (enExample)